AU4766100A - Phospholipase a2-specific inhibiting compounds - Google Patents

Phospholipase a2-specific inhibiting compounds

Info

Publication number
AU4766100A
AU4766100A AU47661/00A AU4766100A AU4766100A AU 4766100 A AU4766100 A AU 4766100A AU 47661/00 A AU47661/00 A AU 47661/00A AU 4766100 A AU4766100 A AU 4766100A AU 4766100 A AU4766100 A AU 4766100A
Authority
AU
Australia
Prior art keywords
phospholipase
inhibiting compounds
specific inhibiting
specific
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU47661/00A
Other languages
English (en)
Inventor
Leon Assogba
Chang-Zhi Dong
Jean-Jacques Godfroid
Francoise Heymans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Paris Diderot Paris 7
Original Assignee
Universite Paris Diderot Paris 7
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Paris Diderot Paris 7 filed Critical Universite Paris Diderot Paris 7
Publication of AU4766100A publication Critical patent/AU4766100A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C07D291/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU47661/00A 1999-05-19 2000-05-19 Phospholipase a2-specific inhibiting compounds Abandoned AU4766100A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9906366A FR2793791B1 (fr) 1999-05-19 1999-05-19 Nouveaux composes inhibiteurs specifiques de phospholipases a2
FR9906366 1999-05-19
PCT/FR2000/001386 WO2000071118A1 (fr) 1999-05-19 2000-05-19 Composes inhibiteurs specifiques de la phospholipase a¿2?

Publications (1)

Publication Number Publication Date
AU4766100A true AU4766100A (en) 2000-12-12

Family

ID=9545771

Family Applications (1)

Application Number Title Priority Date Filing Date
AU47661/00A Abandoned AU4766100A (en) 1999-05-19 2000-05-19 Phospholipase a2-specific inhibiting compounds

Country Status (3)

Country Link
AU (1) AU4766100A (fr)
FR (1) FR2793791B1 (fr)
WO (1) WO2000071118A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2833261B1 (fr) * 2001-12-06 2004-07-02 Yang Ji Chemical Company Ltd Nouveaux composes inhibiteurs specifiques de la phospholipase a2 secretee non pancreatique humaine du groupe ii
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
DE10226934A1 (de) * 2002-06-17 2003-12-24 Bayer Ag Regulation der sPLA2G2A
US7521473B2 (en) 2004-02-25 2009-04-21 Wyeth Inhibitors of protein tyrosine phosphatase 1B
US8884034B2 (en) 2009-07-08 2014-11-11 Dermira (Canada), Inc. TOFA analogs useful in treating dermatological disorders or conditions
EP2822931B1 (fr) 2012-03-09 2017-05-03 Inception 2, Inc. Composés de triazolone et leurs utilisations
MX2015007433A (es) 2012-12-20 2015-12-07 Inception 2 Inc Compuestos de triazolona y usos de los mismos.
EA201690230A1 (ru) 2013-09-06 2016-07-29 Инсепшн 2, Инк. Соединения триазолона и их применения
RS65417B1 (sr) 2014-01-24 2024-05-31 Turning Point Therapeutics Inc Diaril makrocikli kao modulatori protein kinaza
WO2017004342A1 (fr) 2015-07-02 2017-01-05 Tp Therapeutics, Inc. Macrocycles de diaryle chiraux à utiliser en tant que modulateurs de protéines kinases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005368A1 (fr) * 1993-08-13 1995-02-23 Zeneca Limited Derives de thia et oxadiazole utilises comme fongicides et insecticides
CN1115576A (zh) * 1993-10-15 1996-01-24 盐野义制药株式会社 具有细胞浆磷脂酶a2抑制活性的噁唑啉酮衍生物
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
US6353128B1 (en) * 1996-12-03 2002-03-05 Eli Lilly And Company Phenyl acetamides as sPLA2 inhibitors

Also Published As

Publication number Publication date
FR2793791A1 (fr) 2000-11-24
WO2000071118A1 (fr) 2000-11-30
FR2793791B1 (fr) 2002-01-25

Similar Documents

Publication Publication Date Title
AU5413600A (en) Compounds
AU1071301A (en) Pharmaceutical compounds
AU1278701A (en) Novel compounds
AU2408300A (en) Novel compounds
AU1746401A (en) Compounds
AU6032100A (en) New compounds
AU4766100A (en) Phospholipase a2-specific inhibiting compounds
AU3997700A (en) Anti-first-pass effect compounds
AU2608301A (en) Methods for inhibiting mastocytosis
AU5935600A (en) Phosphoramide compounds
AU2001289588A1 (en) Phospholipase from zygoascus hellenicus
AU5722900A (en) Pharmaceutical compounds
AU6480299A (en) Pharmaceutical compounds
AU4132200A (en) Novel compounds
AUPQ319899A0 (en) Amide compounds
AU2109700A (en) Novel compounds
AU5787901A (en) Compound
AU5184599A (en) Pharmaceutical compounds
AU5119400A (en) Compounds
AU2288900A (en) Novel compounds
AUPQ386899A0 (en) Peptide compounds
AU6168900A (en) Compounds
AU2668000A (en) Bis-styrylbiphenyl compounds
AU4156800A (en) Novel compounds
AU7784700A (en) Novel compounds

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase